Glaxosmithkline Share News (GSK)

WRAPUP 3-West Africa Ebola outbreak could infect 20,000 people, WHO says

* Number of cases possibly 2-4 times higher than reported * 12,000 local staff, 750 international experts needed * Nigeria reports spread to main African oil hub * Air service suspension threatens aid operation - WHO (Adds Liberian president) By Stephanie Nebehay and Tim

Gene studies of Ebola in Sierra Leone show virus is mutating fast

By Julie Steenhuysen CHICAGO, Aug 28 (Reuters) - Genetic studies of some of the earliest Ebola cases in Sierra Leone reveal more than 300 genetic changes in the virus as it leapt from person to person, changes that could blunt the effectiveness of diagnostic tests and experimental treatment

WRAPUP 2-West Africa Ebola outbreak could infect 20,000 people, WHO says

* Number of cases possibly 2-4 times higher than reported * 12,000 local staff, 750 international experts needed * Nigeria reports spread to main African oil hub * Air service suspension threatens aid operation - WHO (Adds details, quotes) By Stephanie Nebehay and Tim Co

CORRECTED-WRAPUP 1-West Africa Ebola outbreak could infect 20,000 people, WHO says

(Corrects to show dead doctor did not treat Sawyer) * Number of cases possibly 2-4 times higher than reported * 12,000 local staff, 750 international experts needed * Operation to combat outbreak to cost $490 mln * Nigeria reports possible spread to main African oil hub</p

WRAPUP 1-West Africa Ebola outbreak could infect 20,000 people, WHO says

* Number of cases possibly 2-4 times higher than reported * 12,000 local staff, 750 international experts needed * Operation to combat outbreak to cost $490 mln * Nigeria reports possible spread to main African oil hub (Adds Nigeria case, GSK vaccine testing, details) By

UPDATE 1-Ebola vaccine from GSK fast-tracked into clinical trials

* Trials to vaccinate healthy volunteers from mid-September * Planned stockpile of up to 10,000 doses for early use * GSK working with U.S. NIH and international consortium * U.S. researchers also testing Canadian Ebola vaccine (Updates with further details on clinical trial p

GSK to begin testing Ebola vaccine on humans

Glaxosmithkline has been given permission to begin testing its Ebola virus vaccine on humans next week. The drugs giant and its partner on the experimental treatment, the US National Institutes of Health's Vaccine Research Centre, have been granted approval by the US Food and Drug Administration to

GSK Ebola vaccine fast-tracked into U.S., UK and African trials

LONDON, Aug 28 (Reuters) - An experimental Ebola vaccine from GlaxoSmithKline is being fast-tracked into human studies and the company plans to build up a stockpile of up to 10,000 doses for emergency deployment, if results are good. Britain's biggest drugmaker said on Thursday the research

Ebola vaccine from GSK to begin U.S. clinical trials within weeks-sources

By Sharon Begley NEW YORK, Aug 27 (Reuters) - U.S. health officials will announce on Thursday that a human study of an Ebola vaccine made by GlaxoSmithKline will begin within a couple of weeks and not later this year as the company estimated originally, according to people familiar with the

UK MIDDAY BRIEFING: RBS Fined Again; Foxtons Warns Of Cooling Market

TOP NEWS: Big UK Supermarkets Continue To Feel Squeeze - Kantar

UK MORNING BRIEFING: Shares Open Flat To Higher But Foxtons Falls

Glaxo Says FDA Approves Promacta SNDA In Aplastic Anaemia Patients

UK MIDDAY BRIEFING: Antofagasta And Petrofac Slump Despite Confidence

TOP NEWS: UK Mortgage Approvals Decline Unexpectedly In July